New Student Offer - Use Code HELLO

Register Now

SII Launches HPV Vaccine

Published on September 02, 2022
Current Context: The Serum Institute of India (SII) and the Department of Biotechnology (DBT) launched the first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine, CERVAVAC for the prevention of cervical cancer.
SII Launches HPV Vaccine
  • It will be the first Quadrivalent Human Papilloma Virus vaccine (qHPV) in India, to prevent cervical cancer.
  • The HPV vaccine protects against the types of HPV that most often cause vulvar, cervical, and vaginal cancers.
  • For 9-14 year-olds, the vaccine will be in two doses & for 15-26 year-olds it will be a three-dose schedule.
  • Cervical cancer starts in the cervix and according to the Centers for Disease Control and Prevention (CDCP), all women are at risk for cervical cancer.
  • According to the World Health Organization (WHO) data, more than 4 million women have died due to cervical cancer in India since 2019.
  • Serum Institute of India was founded by Dr. Cyrus Poonawalla in 1966 and has headquarters in Pune, Maharashtra.


Q.1 Human Papilloma Virus causes which disease?
a. Leukemia
c. Hepatitis-B
d. Cervical Cancer
ebook store

About us

ramandeep singh

Ramandeep Singh, your guide to banking and insurance exams. With 14 years of experience and 5000+ selections, Ramandeep understands the path to success, having transitioned himself from Dena Bank and SBI. He's passionate about helping you achieve your banking and insurance dreams.

  • Follow me:
Close Menu
Close Menu